Company Filing History:
Years Active: 2016
Title: The Innovations of Benoit Pelletier
Introduction
Benoit Pelletier is a notable inventor based in Chambly, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of assays for cancer treatment.
Latest Patents
Pelletier holds a patent for an "Assay for inhibitors of CIP/KIP protein degradation." This innovative assay and system are compatible with high throughput screening (HTS) and are capable of identifying inhibitors, such as small-molecule inhibitors, that prevent the degradation of the Cdk inhibitor p21. The assay utilizes a fusion protein that includes a p2 polypeptide and a reporter protein linked to the C-terminal of the p21 polypeptide. This fusion protein has a half-life similar to that of the p21 polypeptide. The inhibitors identified through this assay may be instrumental in inhibiting the proliferation of tumor cells, thus offering potential treatments for various cancers.
Career Highlights
Benoit Pelletier is affiliated with the Université de Montréal, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cancer therapies.
Collaborations
Pelletier collaborates with esteemed colleagues, including Anne Marinier and Sylvain Meloche, who contribute to his research endeavors.
Conclusion
Benoit Pelletier's innovative work in developing assays for cancer treatment showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his patent reflects the potential for significant breakthroughs in this field.